Research on the Value Evaluation of Biomedical Enterprises under EVA and B-S Models—A Case Study of Yiling Pharmaceutical

随着生物技术的高速发展，医药行业成为国家优先发展的战略性领域。在国家政策的支持下，生物医药企业得到了快速发展。这种情况下，生物医药企业的价值评估变得更加紧迫，以适应市场变化和投资需求，更好地吸引投资和促进医药行业的健康发展。而传统的价值评估方面已无法适用生物医药企业现在的情形，而EVA和B-S组合模型的出现打破了这一局面。本文基于EVA和B-S模型，结合以岭药业2018~2022年的财务数据预测其企业价值，为投资者进行选择提供了参考。With the rapid development of biotechnology, the pharmaceutical industry has become a strategic field prioritized by the nation. With support from national policies, biopharmaceutical companies have developed rapidly. In this context, the valuation of biopharmaceutical companies has become increasingly urgent in adapting to market changes and investment needs, in order to better attract investment and promote the healthy development of the pharmaceutical industry. Meanwhile, traditional valuation methods can no longer apply to the current situation of biopharmaceutical companies, and the emergence of the EVA and B-S combination models has overturned this scenario. This paper, based on the EVA and B-S models, predicts the value of Yiling Pharmaceutical Co., Ltd. using its financial data from 2018 to 2022, providing a reference for investors in making decisions.